Correlation Between Acrivon Therapeutics, and ARCA Biopharma

Can any of the company-specific risk be diversified away by investing in both Acrivon Therapeutics, and ARCA Biopharma at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Acrivon Therapeutics, and ARCA Biopharma into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Acrivon Therapeutics, Common and ARCA Biopharma, you can compare the effects of market volatilities on Acrivon Therapeutics, and ARCA Biopharma and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Acrivon Therapeutics, with a short position of ARCA Biopharma. Check out your portfolio center. Please also check ongoing floating volatility patterns of Acrivon Therapeutics, and ARCA Biopharma.

Diversification Opportunities for Acrivon Therapeutics, and ARCA Biopharma

0.03

Correlation Coefficient

Acrivon Therapeutics,  ARCA Biopharma

Significant diversification

The 3 months correlation between Acrivon and ARCA is 0.03. Overlapping area represents the amount of risk that can be diversified away by holding Acrivon Therapeutics, Common and ARCA Biopharma in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on ARCA Biopharma and Acrivon Therapeutics, is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Acrivon Therapeutics, Common are associated (or correlated) with ARCA Biopharma. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of ARCA Biopharma has no effect on the direction of Acrivon Therapeutics, i.e., Acrivon Therapeutics, and ARCA Biopharma go up and down completely randomly.

Pair Corralation between Acrivon Therapeutics, and ARCA Biopharma

Given the investment horizon of 90 days Acrivon Therapeutics, Common is expected to generate 0.75 times more return on investment than ARCA Biopharma. However, Acrivon Therapeutics, Common is 1.34 times less risky than ARCA Biopharma. It trades about 0.02 of its potential returns per unit of risk. ARCA Biopharma is currently generating about -0.02 per unit of risk. If you would invest  1,152  in Acrivon Therapeutics, Common on September 20, 2024 and sell it today you would lose (431.00) from holding Acrivon Therapeutics, Common or give up 37.41% of portfolio value over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Insignificant
Accuracy	84.85%
Values	Daily Returns

Acrivon Therapeutics, Common  vs.  ARCA Biopharma

Acrivon Therapeutics,

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Acrivon Therapeutics, Common has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of fairly stable basic indicators, Acrivon Therapeutics, is not utilizing all of its potentials. The latest stock price fuss, may contribute to near-short-term losses for the sophisticated investors.

ARCA Biopharma

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days ARCA Biopharma has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of very healthy forward indicators, ARCA Biopharma is not utilizing all of its potentials. The latest stock price disarray, may contribute to short-term losses for the investors.

Pair Trading with Acrivon Therapeutics, and ARCA Biopharma

The main advantage of trading using opposite Acrivon Therapeutics, and ARCA Biopharma positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Acrivon Therapeutics, position performs unexpectedly, ARCA Biopharma can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in ARCA Biopharma will offset losses from the drop in ARCA Biopharma's long position.

The idea behind Acrivon Therapeutics, Common and ARCA Biopharma pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Stocks Directory module to find actively traded stocks across global markets.